Keyword: Ionis Pharmaceuticals
Eidos' $106 million IPO comes on the heels of a $64 million series B and will support phase 2 and phase 3 trials of its TTR amyloidosis drug.
Scientists have developed a small molecule that can selectively target RNA and could pave the way for a pill that can treat genetic diseases.
After a turbulent year, Prothena is reorganizing to rally its resources around what remains in its neuroscience pipeline.
An FDA panel voted 12-8 to recommend the approval of Akcea's volanesorsen, an RNAi drug for a rare lipid disorder.
Alnylam is gearing up to move RNAi therapies for central nervous system disorders into the clinic.
Akcea suffered the setback after the FDA asked for more time to review its response to requests for information on the rare disease antisense drug.
This comes after two other biotechs had to pull their attempts last week.
The new angle comes from an exploratory post hoc analysis which linked the RNAi therapy to a 50% drop in hospitalization and mortality over placebo.
Biogen is paying a $375 million fee and splurging $625 million on Ionis’ stock for a chance to pick up a series of neurological antisense drugs.
The Big Pharma is paying $30 million upfront to pick up the rights to the program and take it into the clinic.